| Pete Kwabena Obeng, MD | |
|
292 Frantz Rd, Ste 102, Stroudsburg, PA 18360 | |
| (570) 476-3336 | |
| (570) 426-2979 |
| Full Name | Pete Kwabena Obeng |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 292 Frantz Rd, Ste 102, Stroudsburg, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801112834 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Pete Kwabena Obeng, MD 292 Frantz Rd, Ste 102, Stroudsburg, PA 18360 Ph: (570) 476-3336 | Pete Kwabena Obeng, MD 292 Frantz Rd, Ste 102, Stroudsburg, PA 18360 Ph: (570) 476-3336 |
News Archive
Aruba Networks, Inc., a global leader in distributed enterprise network solutions, today announced that Thailand's Khon Kaen University Faculty of Medicine has deployed its adaptive Wi-Fi networks and AirWave Wireless Management System to support X-Ray image archiving, healthcare and drug dosage record access, and Internet access to 2,000 staff members and 1,200 students. The new system replaces legacy Cisco and 3COM autonomous FAT access points, and was deployed by Aruba authorized partner World Information Technology Company.
Stem cells are the body's mechanics, repairing damaged tissues and organs. Because these cells are able to grow into any type of cell in the body, scientists believe they hold the key to groundbreaking new therapies. To help further this research, scientists from the University of Victoria have found a new way to culture cells in 3D- a significant step forward for regenerative medicine.
A possible 'first-line' treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
The anti-leukemia drug dexamethasone contributes to a relentless fatigue and poor quality of sleep in children undergoing treatment for acute lymphoblastic leukemia (ALL), according to a new study from St. Jude Children's Research Hospital.
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company's newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL's U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.
› Verified 8 days ago